At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The Trump administration is considering eliminating dozens of programs at HHS amid a mass reorganization of the agency.

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...

The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...

Advisory Committee on Immunization Practices (ACIP) has voted to expand its recommendation for the use of respiratory ...